Clinical trial
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST)…
NCT00276302 · Infinity Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00276302 |
|---|---|
| Title | Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) |
| Official title | A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Either Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) or Advanced or Metastatic Soft Tissue Sarcomas (STS) |
| Lead sponsor | Infinity Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas |
| Intervention type | Drug |
| Interventions | IPI-504 |
| Enrollment | 63 |
| Start date | Dec 1, 2005 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Jan 13, 2006 |
| Last update posted | Jan 6, 2011 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: